FindMyKOL
Clinical trialNCT01840826CompletedInterventional

Reducing Hospital Readmissions in Patients With Depressive Symptoms

NCT01840826 is an interventional trial sponsored by Boston Medical Center. As of 18 Nov 2026, it is completed. It studies Depression. The registry lists an enrollment of 709 participants at 1 site in 1 country. The registry lists a start date of 28 Feb 2013 and a primary completion date of 28 Feb 2018.

SponsorBoston Medical Center →Enrollment709Depression
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01840826
FieldValue
Registry IDNCT01840826
StatusCompleted
Study typeInterventional trial
Lead sponsorBoston Medical Center
Enrollment709
Registered sites1
Countries1
ConditionsDepression
Start28 Feb 2013
Primary completion28 Feb 2018
Study completion28 Feb 2018
Last update posted7 Mar 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Project Re-Engineered Discharge (Project RED) has previously demonstrated that patients who received the RED were 30% less likely than patients receiving usual care to access inpatient or emergency services within 30 days of discharge. In this project, the investigators add a new dimension to RED by integrating screening, referral and treatment for depression into the original RED intervention and determining if this enhanced intervention increases the effectiveness of RED in preventing readmissions and controlling costs in the 180 days after discharge for patients with signs of depression.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States1 site
  • Boston Medical Center

    Boston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT01840826

Each answer restates registry values shown on this page.

What is NCT01840826?

NCT01840826 is an interventional trial sponsored by Boston Medical Center. It studies Depression.

Who leads NCT01840826?

The registry names Brian W Jack, MD (principal investigator, Boston University) as the overall official.

Where does NCT01840826 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When did NCT01840826 end?

The registry lists a primary completion date of 28 Feb 2018 and a study completion date of 28 Feb 2018. The sponsor last updated the record on 7 Mar 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.